{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T12:29:30Z","timestamp":1720614570441},"reference-count":26,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.dld.2013.07.010","type":"journal-article","created":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T19:07:42Z","timestamp":1380568062000},"page":"S337-S342","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S5","title":["Management of anaemia and other treatment complications"],"prefix":"10.1016","volume":"45","author":[{"given":"Christophe","family":"H\u00e9zode","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2013.07.010_bib0005","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infectious Diseases"},{"key":"10.1016\/j.dld.2013.07.010_bib0010","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of peylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2013.07.010_bib0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-142-2-200501180-00009","article-title":"Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival","volume":"142","author":"Shiratori","year":"2005","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.dld.2013.07.010_bib0020","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2013.07.010_bib0025","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2013.07.010_bib0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"55","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2013.07.010_bib0035","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis c virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2013.07.010_bib0040","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2013.07.010_bib0045","unstructured":"Telaprevir EU Summary of Product Characteristics [online]. Available at http:\/\/www.ema.europa.eu."},{"key":"10.1016\/j.dld.2013.07.010_bib0050","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2013.07.010_bib0055","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2013.07.010_bib0060","unstructured":"Boceprevir EU Summary of Product Characteristics [online]. Available at http:\/\/www.ema.europa.eu."},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2013.07.010_bib0065","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/S0168-8278(11)60479-0","article-title":"Anemia had no effect on efficacy outcomes in treatment-na\u00efve patients who received telaprevir-based regimen in the advance and illuminate phase 3 studies","volume":"54","author":"Sulkowski","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2013.07.010_bib0070","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/hep.26096","article-title":"Anemia during treatment with peginterferon alfa-2b\/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2013.07.010_bib0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.gastro.2006.11.011","article-title":"Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C","volume":"132","author":"Shiffman","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2013.07.010_bib0080","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"issue":"Suppl. 2","key":"10.1016\/j.dld.2013.07.010_bib0085","doi-asserted-by":"crossref","first-page":"S559","DOI":"10.1016\/S0168-8278(12)61430-5","article-title":"A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon\/ribavirin","volume":"56","author":"Poordad","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl","key":"10.1016\/j.dld.2013.07.010_bib0090","first-page":"216A","article-title":"Boceprevir (BOC) combined with peginterferon alfa-2b\/ribavirin (P\/RBV) in treatment-naive chronic HCV genotype 1 patients with compensated cirrhosis: sustained virologic response (SVR) and safety subanalyses from the anemia management study","volume":"56","author":"Lawitz","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.dld.2013.07.010_bib0095","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1016\/S0168-8278(12)61174-X","article-title":"Ribavirin dose reduction in treatment naive and previously treated patients who received telaprevir-combination treatment: no impact on SVR in phase 3 studies","volume":"56","author":"Sulkowski","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2013.07.010_bib0100","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1365-2133.2005.06931.x","article-title":"Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases","volume":"153","author":"L\u00fcbbe","year":"2005","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.dld.2013.07.010_bib0105","first-page":"29","article-title":"Dermatological side effects","volume":"9","author":"L\u00fcbbe","year":"2008","journal-title":"Hot Topics in Viral Hepatitis"},{"key":"10.1016\/j.dld.2013.07.010_bib0110","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2011.08.006","article-title":"Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals","volume":"56","author":"Cacoub","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2013.07.010_bib0115","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000318904","article-title":"Drug rash with eosinophillia and systemic symptoms due to telaprevir","volume":"221","author":"Montaudi\u00e9","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.dld.2013.07.010_bib0120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.329.7457.101","article-title":"Initial management of a major burn: II \u2013 Assessment and resuscitation","volume":"329","author":"Hettiaratchy","year":"2004","journal-title":"British Medical Journal"},{"key":"10.1016\/j.dld.2013.07.010_bib0125","first-page":"374A","article-title":"Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon\/ribavirin treatment failure: subanalysis of the REALIZE phase III study","volume":"54","author":"Pol","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2013.07.010_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC)","author":"H\u00e9zode","year":"2013","journal-title":"Journal of Hepatology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865813002533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865813002533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T09:56:14Z","timestamp":1539338174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865813002533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":26,"alternative-id":["S1590865813002533"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2013.07.010","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of anaemia and other treatment complications","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2013.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}